For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 57,621 | -49,380* | 365,053 | 409,937 |
| General and administrative | 1,247,077 | 671,628.5* | 1,739,174 | 1,634,195 |
| Impairment of in-process research and development | - | -9,323,951.5* | 18,647,903 | - |
| Total operating expenses | 1,304,698 | -8,701,703 | 20,752,130 | 2,044,132 |
| Gain from operations | -1,304,698 | 8,701,703* | -20,752,130 | -2,044,132 |
| Interest expense | -132,512 | -121,130* | -131,350 | -130,036 |
| Fair value option loss on convertible notes | -344,000 | - | - | - |
| Change in fair value of warrant liabilities | -16,000 | - | - | - |
| Change in fair value of equity payable | 28,171 | 81,807.5* | -226,262 | 37,149 |
| Pre-tax net gain | - | 8,498,765.5* | -20,657,218 | -2,211,317 |
| Income tax benefit (provision) | - | 425,829.5* | -851,659 | 0 |
| Net gain | -1,793,381 | 8,072,936 | -19,805,559 | -2,211,317 |
| Basic EPS | -0.22 | 1.354 | -2.56 | -0.46 |
| Diluted EPS | -0.22 | 1.354 | -2.56 | -0.46 |
| Basic Average Shares | 8,095,921 | 5,963,943* | 7,740,678 | 4,814,115 |
| Diluted Average Shares | 8,095,921 | 5,963,943* | 7,740,678 | 4,814,115 |
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)